Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: Reduction by 2-year antiretroviral therapy

AIDS

Volumn 24, Issue 11, 2010, Pages 1733-1737

  Trøseid, Marius ^a,b   Nowak, Piotr ^a   Nyström, Jessica ^a   Lindkvist, Annica ^a   Abdurahman, Samir ^a   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

antiretroviral therapy; high mobility group box 1 protein; HIV 1; immune activation; lipopolysaccharide; microbial translocation

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 77954349457     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833b254d     Document Type: Article

References (21)

1. Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95:249-255.
2. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5:83-89.
3. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997-1998; 187-228.
4. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
5. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1:23-30.
6. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
7. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-570.
8. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009; 86:573-576.
9. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110:1970-1981.
10. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysacchar-ide-mediated TNF-alpha production in human monocytes. J Immunol 2008; 180:5067-5074.
11. Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. AIDS 2007; 21:869-871.
12. UrbonaviciuteV, Furnrohr BG, Weber C, HaslbeckM, Wilhelm S, Herrmann M, et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007; 81:67-74.
13. Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, Moos V, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 2009; 58:220-227.
14. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720.
15. Lester RT, Yao XD, Ball TB, McKinnon LR, Omange WR, Kaul R, et al. HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One 2009; 4:e5644.
16. Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clin Infect Dis 2007; 45:1214-1220.
17. Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P. An African perspective on mucosal immunity and HIV-1. Mucosal Immunol 2009; 2:300-314.
18. Sonnerborg A, Ayehunie S, Julander I. Elevated levels of circulating tumor necrosis factor alpha in human immunodeficiency virus type 1-infected Africans living in Sweden. Clin Diagn Lab Immunol 1995; 2:118-119.
19. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leu-koc Biol 2007; 81:49-58.
20. Lindkvist A, Nowak P, Troseid M, Abdurahman S, Nystrom J, Sonnerborg A. HMGB1 and bacterial products synergistically induce HIV-1 replication in vitro [abstract #245]. 17th Conference on retroviruses and opportunistic infections; San Fran-sisco, California, USA; 2010.
21. Pine SO, McElrath MJ, Bochud PY. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 2009; 23:2387-2395.